Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mario Sznol

Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Cell

English

Exome Sequencing Identifies Recurrent Somatic RAC1 Mutations in Melanoma

Nature Genetics

Genetics

2012

English

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination With Bevacizumab Versus Sunitinib in Renal Cell Carcinoma

English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology

English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

English

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical Cancer Research

Cancer Research

Oncology

2016

English

Sixth Immunotherapy of Cancer Conference (ITOC): Advances and Perspectives—a Meeting Report

Journal for ImmunoTherapy of Cancer

English

Patterns of Failure After Immunotherapy With Checkpoint Inhibitors Predict Durable Progression-Free Survival After Local Therapy for Metastatic Melanoma

Journal for ImmunoTherapy of Cancer

English

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer

English

A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence

Journal for ImmunoTherapy of Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mario Sznol

Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Exome Sequencing Identifies Recurrent Somatic RAC1 Mutations in Melanoma

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination With Bevacizumab Versus Sunitinib in Renal Cell Carcinoma

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Sixth Immunotherapy of Cancer Conference (ITOC): Advances and Perspectives—a Meeting Report

Patterns of Failure After Immunotherapy With Checkpoint Inhibitors Predict Durable Progression-Free Survival After Local Therapy for Metastatic Melanoma

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence